H. Küpper

7.7k citations

127 papers · 5.9k · 2 hit papers · h-index 37

Impact in

Rheumatology top 0.05%
- Rheumatoid Arthritis Research and Therapies
- Spondyloarthritis Studies and Treatments
- Systemic Lupus Erythematosus Research
Hematology top 0.5%
- Autoimmune and Inflammatory Disorders Research

Papers in

Rheumatology 81
- Rheumatoid Arthritis Research and Therapies 59
- Spondyloarthritis Studies and Treatments 27
- Systemic Lupus Erythematosus Research 10
Hematology 25
- Autoimmune and Inflammatory Disorders Research 22

Co-authors: Robert Wong (13 shared papers)Désirée van der Heijde (15 shared papers)Joachim Sieper (8 shared papers)S. Kary (15 shared papers)Martín Rudwaleit (10 shared papers)Jürgen Braun (6 shared papers)Alan Kivitz (6 shared papers)Maxime Dougados (4 shared papers)
Journals: Annals of the Rheumatic Diseases (32 papers)Lara D. Veeken (14 papers)The Journal of Rheumatology (8 papers)Arthritis Research & Therapy (5 papers)Pediatric Rheumatology (4 papers)
Partner nations: Germany United States Netherlands

In The Last Decade

H. Küpper

118 papers receiving 5.7k citations

H. Küpper's Hit Papers

align trajectories log scale

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trial 2006 · 665 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2006 Arthritis & Rheumatism
2004 Annals of the Rheumatic Diseases

Peers

Countries citing papers authored by H. Küpper

Since Specialization

Citations

This map shows the geographic impact of H. Küpper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Küpper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Küpper more than expected).

Fields of papers citing papers by H. Küpper

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Küpper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Küpper. The network helps show where H. Küpper may publish in the future.

Co-authors

The 25 scholars most cited alongside H. Küpper, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with H. Küpper Line = papers co-authored together H. Küpper links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 127 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trial Arthritis & Rheumatism ·Désirée van der Heijde, Alan Kivitz, Michael Schiff, Joachim Sieper, Ben A. C. Dijkmans, Jürgen Braun, Maxime Dougados, John D. Reveille, Robert Wong, H. Küpper, John C. Davis Hit paper breakdown →	2006	665
2	Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed Annals of the Rheumatic Diseases ·L.B.A. van de Putte, Catherine Atkin, Michel Malaise, J Sany, Anthony S. Russell, P L C M van Riel, Loukas Settas, J. W. J. Bijlsma, S Todesco, Maxime Dougados, Peter Nash, Paul Emery, Nike Walter, Martin Kaul, Steven Fischkoff, H. Küpper Hit paper breakdown →	2004	513
3	Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years Arthritis Research & Therapy ·Désirée van der Heijde, David Salonen, Barbara N. Weissman, Robert Landewé, Walter P. Maksymowych, H. Küpper, Shaila Ballal, E Gibson, Robert Wong, (unknown)	2009	307
4	Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve‐week randomized, double‐blind, placebo‐controlled trial followed by an open‐label extension up to week fifty‐two Arthritis & Rheumatism ·Hildrun Haibel, Martín Rudwaleit, Joachim Listing, F. Heldmann, Robert Wong, H. Küpper, Jürgen Braun, Joachim Sieper	2008	232
5	Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial The Lancet ·Josef S Smolen, Paul Emery, Roy Fleischmann, Ronald van Vollenhoven, Karel Pavelká, Patrick Durez, B. Guérette, H. Küpper, Laura Redden, (unknown), Arthur Kavanaugh	2013	213
6	Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study Annals of the Rheumatic Diseases ·Martín Rudwaleit, E Rødevand, Peter Holck, J. Vanhoof, Martina Kron, S. Kary, H. Küpper	2008	209
7	Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial Annals of the Rheumatic Diseases ·Gerd‐Rüdiger Burmester, Alan Kivitz, H. Küpper, Udayasankar Arulmani, S. Florentinus, Sandra Goss, Suchitrita S. Rathmann, Roy Fleischmann	2014	185
8	Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis Lara D. Veeken ·Margaret C. Reilly, Katherine Gooch, Robert Wong, H. Küpper, Désirée van der Heijde	2010	184
9	Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study Annals of the Rheumatic Diseases ·Arthur Kavanaugh, Roy Fleischmann, Paul Emery, H. Küpper, Laura Redden, B. Guérette, Sourav Santra, Josef S Smolen	2012	182
10	Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study Critical Care Medicine ·Konrad Reinhart, T. Menges, Bengt Gårdlund, Jan H. Zwaveling, Mark Smithes, Jean‐Louis Vincent, José M. Tellado, Antonio Salgado-Remigio, Reuven Zimlichman, Stuart Withington, Klaus Tschaikowsky, Rainer Brase, Pierre Damas, H. Küpper, J. Kempeni, Juergen Eiselstein, Martin Kaul	2001	180
11	Effectiveness, Safety, and Predictors of Good Clinical Response in 1250 Patients Treated with Adalimumab for Active Ankylosing Spondylitis The Journal of Rheumatology ·Martín Rudwaleit, Pascal Claudepierre, P Wordsworth, Eduardo Loza Cortina, Joachim Sieper, Martina Kron, Roberto Carcereri-De-Prati, H. Küpper, S. Kary	2009	171
12	Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial Annals of the Rheumatic Diseases ·Gerd R Burmester, X. Mariette, Carlomaurizio Montecucco, Indalecio Monteagudo‐Sáez, Michel Malaise, Athanasios G. Tzioufas, J. W. J. Bijlsma, Kristina Unnebrink, S. Kary, H. Küpper	2007	162
13	Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice Lara D. Veeken ·Stefano Bombardieri, A. A. Ruiz, Patrice Fardellone, Piet Geusens, Frank McKenna, Kristina Unnebrink, U. Oezer, S. Kary, H. Küpper, G. R. Burmester	2007	153
14	A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. PubMed ·Alfons A den Broeder, Leo van de Putte, Rolf Rau, M Schattenkirchner, Piet L. C. M. van Riel, Oliver Sander, Christina Binder, Helmut Fenner, Y. Bankmann, Raja Velagapudi, J. Kempeni, H. Küpper	2002	146
15	Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial Annals of the Rheumatic Diseases ·Désirée van der Heijde, Michael Schiff, Joachim Sieper, Alan Kivitz, Robert Wong, H. Küpper, Ben A. C. Dijkmans, Philip J. Mease, John C. Davis	2008	140
16	Effect of the early use of the anti–tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis Arthritis Care & Research ·Victoria Bejarano, Mark Quinn, Philip G. Conaghan, Richard J. Reece, Anne‐Maree Keenan, David Walker, Andrew Gough, Michael Green, Dennis McGonagle, Ade Adebajo, Stephen Jarrett, Sheelagh Doherty, Lesley Hordon, R D Melsom, Kristina Unnebrink, H. Küpper, Paul Emery	2008	137
17	Adalimumab reduces spinal symptoms in active ankylosing spondylitis: Clinical and magnetic resonance imaging results of a fifty‐two–week open‐label trial Arthritis & Rheumatism ·Hildrun Haibel, Martín Rudwaleit, H. Brandt, Zarho Grozdanovic, Joachim Listing, H. Küpper, Jürgen Braun, Joachim Sieper	2006	119
18	Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions Annals of the Rheumatic Diseases ·Filip Van den Bosch, Bernhard Manger, Philippe Goupille, Neil McHugh, E Rødevand, Peter Holck, Ronald van Vollenhoven, Marjatta Leirisalo‐Repo, Oliver FitzGerald, Martina Kron, Michael Frank, S. Kary, H. Küpper	2009	100
19	Relationship between Interleukin‐6 Plasma Concentration in Patients with Sepsis, Monocyte Phenotype, Monocyte Phagocytic Properties, and Cytokine Production Clinical Infectious Diseases ·Andreas Spittler, Martina Razenberger, H. Küpper, Martin Kaul, Werner O. Hackl, George Boltz‐Nitulescu, R. Függer, Erich Roth	2000	94
20	A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study British Journal of Dermatology ·Diamant Thaçi, J.‐P. Ortonne, Sergio Chimenti, Pierre‐Dominique Ghislain, Petr Arenberger, Knud Kragballe, J-H. Saurat, A. Khemis, P Sprøgel, H.-U. Esslinger, Kristina Unnebrink, H. Küpper	2010	92

About H. Küpper

H. Küpper is a scholar working on Rheumatology, Hematology, Immunology, Genetics and Speech and Hearing, having authored 127 papers that have together received 5.9k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (59 papers), Spondyloarthritis Studies and Treatments (27 papers), Autoimmune and Inflammatory Disorders Research (22 papers), Chronic Lymphocytic Leukemia Research (14 papers), Adolescent and Pediatric Healthcare (12 papers), Systemic Lupus Erythematosus Research (10 papers), Acute Lymphoblastic Leukemia research (9 papers) and Lymphoma Diagnosis and Treatment (8 papers). The work is most often cited by research in Rheumatology (4.2k citations), Hematology (1.0k citations), Immunology (1.4k citations), Ophthalmology (191 citations) and Genetics (217 citations). H. Küpper has collaborated with scholars based in Germany, United States and Netherlands. Frequent co-authors include Robert Wong, Désirée van der Heijde, Joachim Sieper, S. Kary, Martín Rudwaleit, Jürgen Braun, Alan Kivitz, Maxime Dougados, John C. Davis and Martina Kron. Their work appears in journals such as Annals of the Rheumatic Diseases, Lara D. Veeken, The Journal of Rheumatology, Arthritis Research & Therapy and Pediatric Rheumatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

H. Küpper

Impact in

Papers in i

In The Last Decade

H. Küpper

H. Küpper's Hit Papers

Peers

Countries citing papers authored by H. Küpper

Fields of papers citing papers by H. Küpper

All Works

About H. Küpper

Explore authors with similar magnitude of impact

Papers in